10:13 AM EST - Knight Therapeutics Inc. : Announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for NIKTIMVO® (axatilimab) for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients six years and older. Knight Therapeutics Inc.
shares T.GUD are trading up $0.01 at $6.41.
